Communiqués Fortress Biotech, Inc. Nasdaq

Actions

FBIO.P

US34960Q2084

Marché Fermé - Nasdaq Autres places de cotation 21:58:22 07/06/2024			Varia. 5j.	Varia. 1 janv.
16,73 ^USD	+1,70%		+5,42%	+40,94%

15/05	Fortress Biotech, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
14/05	Fortress Biotech annonce que le premier patient a été traité dans le cadre de l'étude de phase 2 du Triplex	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	16/05	AQ
Fortress Biotech: Q1 Earnings Snapshot	15/05	AQ
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	15/05	AQ
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	15/05	AQ
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	14/05	AQ
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	13/05	AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	07/05	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	01/05	AQ
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	25/04	AQ
Avenue Therapeutics Announces Reverse Stock Split	24/04	AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	28/03	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	21/03	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18/03	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15/03	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13/03	AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference	12/03	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11/03	AQ
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	04/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Fortress Biotech, Inc. Nasdaq

Actions

FBIO.P

US34960Q2084

Communiqués

Filtres